CraniUS Therapeutics Secures $20M Series B to Advance Blood-Brain Barrier Bypass Platform
核心洞察
CraniUS Therapeutics (搜索) raised $20 million in Series B financing to accelerate development of NeuroPASS (搜索)™, a fully implantable skull-embedded platform designed to bypass the blood-brain barrier (搜索) for targeted drug delivery.
The neurotechnology company was founded by Dr. Chad Gordon, a Johns Hopkins neuroplastic surgeon, to address the clinical challenge that life-saving therapies often cannot reach the brain due to the blood-brain barrier (搜索).
The funding will support operations into 2027 and enable regulatory submissions, manufacturing scale-up, and product testing towards future commercialization of the multi-product platform.
CraniUS Therapeutics (搜索) LLC has closed a $20 million Series B financing round to advance its NeuroPASS (搜索)™ platform, a fully implantable, skull-embedded system designed to bypass the blood-brain barrier (搜索) and enable targeted drug delivery directly to brain tissue. The Baltimore-based neurotechnology company announced the funding will accelerate development of what it describes as a fundamentally new approach to treating neurological diseases (搜索) and brain cancer (搜索).
Revolutionary Approach to Brain Drug Delivery
The NeuroPASS (搜索)™ platform represents a departure from traditional drug delivery methods by leveraging the temporal cranial space to circumvent the blood-brain barrier (搜索), which has historically prevented many therapeutic compounds from reaching the brain. Dr. Chad Gordon, founder and executive chair of CraniUS Therapeutics (搜索), emphasized the platform's potential impact: "This is not an incremental advance—it represents a fundamentally new approach to treating neurological disease and brain cancer (搜索). We set out to build a platform that could help address a therapeutic barrier that has limited care for decades."
Dr. Gordon, a Johns Hopkins neuroplastic surgeon and pioneer in the field of Neuroplastic Surgery, founded the company after encountering a persistent clinical challenge in practice. He observed that patients with devastating neurological diseases (搜索) often succumbed not because surgery could not help, but because life-saving medicinal therapies could not reach the brain due to the blood-brain barrier (搜索).
Multi-Product Platform Development
NeuroPASS (搜索)™ is being developed as a multi-product platform with an initial roadmap of three complementary products intended to progressively expand therapeutic capability. The devices are designed to evolve cranial implants from passive reconstructive hardware into an active therapeutic interface capable of supporting long-term outpatient care.
The company has spent more than 15 years studying and investigating the temporal cranial space as an optimal site for therapeutic delivery. CraniUS holds 15 issued domestic patents supporting its platform and long-term product roadmap, as well as numerous international patents.
Funding and Commercial Strategy
The Series B financing follows CraniUS's $20 million Series A round in 2022, bringing total capital raised to approximately $40 million. The current round includes $19 million from private investors and $1 million in non-dilutive funding from the State of Maryland. The new capital is expected to support operations into 2027 and will fund regulatory submissions, manufacturing scale-up, and product testing towards future commercialization.
Strategic Board Addition
In February 2026, CraniUS strengthened its leadership team by appointing Oray B. Boston Jr. to its Board of Directors. Boston brings more than 35 years of global leadership experience across medical devices and pharmaceuticals from his tenure at Johnson & Johnson, where he held senior executive leadership roles within DePuy Synthes, most recently serving as Worldwide President of Trauma, Extremities, Craniomaxillofacial, Sports and Animal Health.
"CraniUS is advancing a differentiated approach to drug delivery for neurological disease," said Boston. "I look forward to supporting the company as it progresses toward clinical and commercial milestones."
Mike Maglin, Chief Executive Officer of CraniUS, highlighted the strategic value of Boston's appointment: "As we advance toward commercialization, Oray's unique leadership experience managing both cranial devices and pharmaceutical platforms, together with in-depth understanding of what lies ahead in neurotechnology innovation, will enhance our Board's ability to guide near-term commercialization strategies and maximize growth-related opportunities."
Addressing Unmet Medical Need
Dr. Stephen Klasko, a member of the CraniUS board of directors, contextualized the platform's significance: "Having led large academic health systems and worked at the intersection of care delivery and innovation, we've put robots in operating rooms and AI in radiology suites, but the blood-brain barrier (搜索) has stubbornly ignored a century of pharmaceutical and medical device innovation. NeuroPASS (搜索) represents exactly the kind of 'why not?' thinking that transforms medicine, not incremental improvement, but a fundamental reimagining of how we access the brain."
The NeuroPASS (搜索)™ platform remains investigational and has not been approved or cleared by the U.S. Food and Drug Administration for clinical use. All described uses are under development and subject to regulatory review as the company advances toward clinical development and regulatory pathways.